| Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial C Parker, R Waters, C Leighton, J Hancock, R Sutton, AV Moorman, ... The Lancet 376 (9757), 2009-2017, 2010 | 370 | 2010 |
| Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1 LM Brown, RL Cowen, C Debray, A Eustace, JT Erler, FCD Sheppard, ... Molecular pharmacology 69 (2), 411-418, 2006 | 174 | 2006 |
| EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications C Schwab, SL Ryan, L Chilton, A Elliott, J Murray, S Richardson, C Wragg, ... Blood, The Journal of the American Society of Hematology 127 (18), 2214-2218, 2016 | 144 | 2016 |
| Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia JAE Irving, A Enshaei, CA Parker, R Sutton, RP Kuiper, A Erhorn, L Minto, ... Blood, The Journal of the American Society of Hematology 128 (7), 911-922, 2016 | 127 | 2016 |
| Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro RG Gieling, CA Parker, LA De Costa, N Robertson, AL Harris, IJ Stratford, ... Journal of enzyme inhibition and medicinal chemistry 28 (2), 360-369, 2013 | 90 | 2013 |
| Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research … S Krishnan, R Wade, AV Moorman, C Mitchell, SE Kinsey, TOB Eden, ... Leukemia 24 (2), 450-459, 2010 | 63 | 2010 |
| Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial C Parker, S Krishnan, L Hamadeh, JAE Irving, RP Kuiper, T Révész, ... The Lancet Haematology 6 (4), e204-e216, 2019 | 51 | 2019 |
| Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 … C Eckert, C Parker, AV Moorman, JAE Irving, R Kirschner-Schwabe, ... European journal of cancer 151, 175-189, 2021 | 41 | 2021 |
| Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia–prospective open cohort analyses of the ALLR3 trial AN Masurekar, CA Parker, M Shanyinde, AV Moorman, JP Hancock, ... PLoS One 9 (10), e108107, 2014 | 41 | 2014 |
| Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton SM Johnson, C Dempsey, C Parker, A Mironov, H Bradley, V Saha Journal of extracellular vesicles 6 (1), 1294339, 2017 | 37 | 2017 |
| Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia J Liu, A Masurekar, S Johnson, S Chakraborty, J Griffiths, D Smith, ... Oncotarget 6 (40), 43048, 2015 | 37 | 2015 |
| Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? KJ Williams, CA Parker, IJ Stratford Oxygen Transport to Tissue XXVI, 285-294, 2005 | 34 | 2005 |
| Hearing the voices of Australian healthcare workers during the COVID-19 pandemic MR Ananda-Rajah, BG Veness, D Berkovic, C Parker, G Kelly, D Ayton medRxiv, 2020.09. 25.20197061, 2020 | 33 | 2020 |
| Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial RK Jackson, M Liebich, P Berry, J Errington, J Liu, C Parker, J Moppett, ... European journal of cancer 120, 75-85, 2019 | 24 | 2019 |
| Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 … AC Ford, A Wright-Hughes, SL Alderson, PL Ow, MJ Ridd, R Foy, ... The Lancet 402 (10414), 1773-1785, 2023 | 21 | 2023 |
| Experiences of personal protective equipment by Australian healthcare workers during the COVID-19 pandemic, 2020: A cross-sectional study D Ayton, SE Soh, D Berkovic, C Parker, K Yu, D Honeyman, R Manocha, ... PLoS One 17 (6), e0269484, 2022 | 21 | 2022 |
| Patient perceived financial burden in haematological malignancies: a systematic review C Parker, D Berkovic, D Ayton, E Zomer, D Liew, A Wei Current Oncology 29 (6), 3807-3824, 2022 | 12 | 2022 |
| Arthritis-related work outcomes experienced by younger to middle-aged adults: a systematic review D Berkovic, AM Briggs, D Ayton, C Parker, I Ackerman Occupational and Environmental Medicine 78 (4), 225-236, 2021 | 12 | 2021 |
| The optimal use of PEG-Asparaginase in relapsed ALL—lessons from the ALLR3 Clinical Trial A Masurekar, C Fong, A Hussain, T Revesz, PM Hoogerbrugge, S Love, ... Blood cancer journal 4 (4), e203-e203, 2014 | 12 | 2014 |
| Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids A Dutta, DN Potier, MJ Walker, OJ Gray, C Parker, M Holland, ... Oncotarget 7 (43), 70822, 2016 | 11 | 2016 |
Anthony MoormanProfessor of Genetic Epidemiology, Newcastle UniversityVerified email at newcastle.ac.uk
